Figure 1: Different price guidelines apply for the AMNOG price negotiations if ≥ 5 % of the study population are German Products with initial market entry after January 1st, 2025 are now benefiting from less strict pricing guidelines if the studies used for AMNOG benefit assessment included ≥ 5 % German patients.
Figure 1: Number of reference prices used by each country Changes to the German pricing system for innovative drugs are now in effect due to the Medical Research Act (Medizinforschungsgesetz, MFG). As of January 1st, 2025, European reference prices will no longer be included in the price negotiations according to § 130b
Figure 1: Requirements, pros and cons for the confidential reimbursement amount in Germany Confidential reimbursement amounts are finally available in Germany. However, the medicinal product and the pharmaceutical company must meet several requirements. Above all, the confidential reimbursement amount will only be available for new medicinal products with initial market entry in
With the SHI Financial Stabilisation Act (GKV-FinStG), the framework conditions for price negotiations for medicinal products in Germany have been made more complex and have been systematically tightened by the legislator to the disadvantage of the pharmaceutical industry. On the one hand the extend of the additional benefit and on the other hand the
We are pleased to inform you that our analysis of confidential reimbursement prices in Germany has been published in the journal "Market Access & Health Policy": Schnorpfeil W, Kiehlmeier S. Einführung vertraulicher Erstattungsbeträge setzt falsche Anreize. Market Access & Health Policy. 2024; 2: 28–31. German article English summary
As part of the dialogue with the pharmaceutical industry, the German government has promised to introduce the option of a confidential reimbursement amount. The aim is to support pharmaceutical companies whose products are subject to a considerable price decrease after undergoing an AMNOG benefit assessment by offering the option to keep the new price confidential.
SAVE THE DATE: 16.01.2024 From 10:00 am to 11:30 am Speakers: Dr. Willi Schnorpfeil, Dr. Angela Lammert We are offering a webinar on the topic of "Price negotiations with the SHI under consideration of the legal changes". The webinar is aimed at managing directors and employees of pharmaceutical companies who are involved in pricing issues
In their 2nd and 3rd reading, the German Parliament has decided further specifications of the new law on the financial stabilisation of the statutory health insurances (GKV-FinStG). As already outlined in the draft of the law, the outcome of the AMNOG benefit assessment will further gain importance for the subsequent price negotiations. In case the
Have a look at our latest update of German price negotiations for drugs that went through the AMNOG benefit assessment. The mean price decrease after negotiations was 28 % for all analysed products, 23 % for orphan drugs and 30 % for non-orphan drugs. If you have any further questions or suggestions, please feel free
The German cabinet, the coalition group of ministers, has decided to introduce the draft bill on the financial stabilization of the statutory health insurance (GKV-FinStG) into the parliamentary process [GKV-Finanzstabilisierungsgesetz - Bundesgesundheitsministerium]. The subjects of the draft bill are amendments to the Social Code Book V, in particular sections § 35a and § 130b, which
WS Value & Dossier GmbH
Your specialists for market access and reimbursement.
Rheinstr. 2
65760 Eschborn
Germany
phone: +49 6173 3941016
fax: +49 6173 39411021
© Copyright 2025 | WS Value Dossier GmbH
